Eliem de­lays a de­pres­sion tri­al, in­def­i­nite­ly post­pones an­oth­er af­ter blam­ing CMC is­sues for low drug ex­po­sure

In the drug R&D world, plans are not set in stone, as Eliem Ther­a­peu­tics ex­hib­it­ed Mon­day with shifts to its de­pres­sion strat­e­gy.

The Seat­tle-UK biotech orig­i­nal­ly want­ed to start two mid-stage de­pres­sion tri­als this year but will have to de­lay one — in ma­jor de­pres­sive dis­or­der — un­til next year and in­def­i­nite­ly post­pone the oth­er in per­i­menopausal de­pres­sion. Back in April, Eliem de­layed the launch­es of both Phase IIa tri­als be­cause the biotech was cu­ri­ous as to why the ex­po­sure was low­er than ex­pect­ed in a Phase Ib study, which tried to prove out the con­cepts of ETX-155 in pho­to­sen­si­tive epilep­sy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER